Safety monitoring: Injections have established protocols
Who Should Consider GLP-1 Therapy FDA indications for weight loss require: BMI 30 (obesity), or BMI 27 (overweight) with at least one weight-related condition hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or similar These thresholds set eligibility, but they don't answer the more important question: who benefits most
The study utilized a single-blind, randomized, placebo-controlled, crossover design, combined with functional magnetic resonance imaging (fMRI), to analyze the performance of 54 participants (30 with normal insulin sensitivity and 24 with impaired insulin sensitivity) on sensory associative learning tasks while receiving liraglutide and placebo treatments
The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health. GLP-1 prescription drugs should not be confused with GLP-1 dietary supplements . These products marketed to boost GLP-1 naturally, promote weight loss, or provide nutritional support for those taking GLP-1 medications contain a variety of dietary supplement ingredients, not actual GLP-1 drugs
Ozempic for Weight Loss: Who Should Try It and Will It Work
NEJM Evid
